Tirzepatide vs semaglutide: which is right for you?
One dual agonist, one GLP-1 agonist. The efficacy gap, the pricing gap, and a clear framework for deciding which fits your goals, budget, and health profile.
The efficacy comparison
Both are incretin-based once-weekly injectables, but they differ mechanistically: semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 agonist. The direct head-to-head, SURMOUNT-5, found tirzepatide reached 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks — a roughly 6.5-percentage-point advantage. On average efficacy, tirzepatide leads clearly. Semaglutide remains highly effective (~14.9% in its own STEP 1 trial) and, crucially, better-studied over multi-year horizons.
The cost comparison
Compounded tirzepatide is generally priced higher than compounded semaglutide. In our July 2026 tracking, flat-rate compounded tirzepatide runs about $186/month versus roughly $145/month for flat-rate compounded semaglutide. On the brand side, both are expensive without insurance — Zepbound near $1,086/month retail, Wegovy near $1,349.
Cost per result
Dividing annual cost by trial-average efficacy is rough but useful. Flat-rate compounded tirzepatide (~$2,232/yr ÷ 20.9%) is about $107 per percentage point; flat-rate compounded semaglutide (~$1,740/yr ÷ 14.9%) is about $117. They're remarkably close — tirzepatide buys more absolute loss for a similar cost-per-point, while semaglutide is a lower monthly commitment. An illustrative comparison, not a clinical claim.
| Factor | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP/GLP-1 | GLP-1 |
| Head-to-head loss (SURMOUNT-5) | 20.2% | 13.7% |
| Flat-rate compounded cost | ~$186/mo | ~$145/mo |
| Cardiovascular outcomes trial | Ongoing (SURMOUNT-MMO) | SELECT (completed) |
| Real-world track record | Newer | Longer |
Who should choose which
Neither drug is universally better; they occupy different points on the efficacy-cost-evidence frontier. Tirzepatide is the stronger choice when maximum average weight loss is the priority and the higher monthly cost is acceptable. Semaglutide is the stronger choice when a lower monthly commitment matters, when a completed cardiovascular-outcomes trial (SELECT) is relevant to your health profile, or when you value the longer real-world track record. Tolerability is individual enough that some people tolerate one markedly better, so a program that allows a penalty-free switch has real option value. What we can say cleanly is the pricing: flat-rate compounded semaglutide is the lower monthly commitment, while tirzepatide buys more average weight loss. Suitability, dose, and switching are clinical decisions for a prescriber who knows your history.
The compounded-market picture
Beyond efficacy and price, the practical availability of each molecule shapes real decisions. In the compounded telehealth market we track, semaglutide programs are slightly more numerous and often a bit cheaper, while tirzepatide programs have expanded quickly as demand shifted toward the more effective agent. Both molecules went through brand shortages that reshaped the compounded landscape, and both are now in a narrower post-shortage regulatory environment where provider transparency matters more than the headline price. A cost-conscious reader is well served by treating the tirzepatide-versus-semaglutide question as the first of several decisions rather than the only one: which molecule, then which pricing model, then which provider on transparency and support. Getting the molecule right but the provider wrong can cost more, in money and outcome, than the efficacy gap between the two drugs. Our editorial pick, NexLife, offers both molecules at flat rates with bundled clinical support, which removes the switching penalty from the equation for patients who want to keep that option open.
Frequently asked questions
Is tirzepatide or semaglutide more effective for weight loss?
In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater average loss (20.2% vs 13.7% over 72 weeks). Semaglutide remains highly effective and often cheaper. The best choice depends on individual priorities and suitability.
Is compounded tirzepatide more expensive than semaglutide?
Generally yes. In July 2026 tracking, flat-rate compounded tirzepatide runs ~$186/month versus ~$145/month for flat-rate compounded semaglutide. Both brand products are expensive without insurance.
Which has better cost-per-result?
They're close. Flat-rate compounded tirzepatide is about $107 per percentage point of trial-average loss; semaglutide about $117. Tirzepatide buys more absolute loss; semaglutide is a lower monthly commitment.
Can I switch between tirzepatide and semaglutide?
Switching is a clinical decision made with a prescriber based on response, tolerability, and goals. Both require their own titration schedules. A program offering both at flat rates removes the cost penalty from switching.
How to actually make the decision
Turning the trade-offs into a decision is easier with a simple sequence. Start with your primary goal: if maximum average weight loss is the single most important thing and the higher monthly cost is acceptable, the head-to-head data point toward tirzepatide. If a lower monthly commitment is decisive, or if you have established cardiovascular disease where semaglutide has a completed outcomes trial (SELECT) that tirzepatide does not yet match, semaglutide has the stronger case. Next, factor tolerability, which is genuinely individual — some people do markedly better on one molecule, and there is no reliable way to predict which in advance, so a program that lets you switch without a penalty or a fresh signup fee protects you against guessing wrong. Then factor availability and pricing in your specific state, since the cheapest advertised option is irrelevant if it is not licensed where you live. Finally, remember that the molecule is only the first of several decisions; the pricing model and the provider transparency you choose afterward will affect your total cost and outcome at least as much as the tirzepatide-versus-semaglutide choice itself. A program offering both molecules at flat rates with bundled clinical support, like our editorial pick, lets you make the molecule decision with your prescriber rather than locking it in at signup for pricing reasons — which is the right way to make what is fundamentally a clinical choice.
References
- Aronne LJ, et al. Tirzepatide vs semaglutide (SURMOUNT-5). N Engl J Med. 2025.
- Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022.
- Wilding JPH, et al. STEP 1 semaglutide. N Engl J Med. 2021.
- WeightLoss GLP-1 July 2026 dataset.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.